Hamamelis water 12.5% / Naphazoline 0.01% eye drops
Available from a pharmacy with pharmacist advice
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
MHRA licensed products
View all licensed products for Hamamelis + Naphazoline on the MHRA register
Optrex Bloodshot eye drops
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Randomised trials: 2 · 2014–2026
Showing the 50 most relevant studies, sorted by most relevant.
Döndü Sevimli Güler, Gülşen Vural, Z. Turan, et al.
Breastfeeding Medicine, 2025
W. F. de Carvalho, L. Júnior, H. F. B. Junior, et al.
The European journal of prosthodontics and restorative dentistry, 2020
A. Rostami-Vartooni, M. Nasrollahzadeh, M. Alizadeh
Journal of Alloys and Compounds, 2016
N. Admuthe, Santosh Karajgi, Jyoti Uikey, et al.
Cureus, 2025
Hemorrhoids are an anorectal problem that is prevalent and commonly managed with corticosteroids, analgesics, and phlebotonics. These conventional treatments are, however, only temporary in serving relief and come with adverse side effects when used long-term. Alternative herbal remedies, created from traditional medicine with all the evidence of their pharmacological action, promise good results. The effectiveness of various botanicals with the potential of being anti-inflammatory, venotonic, astringent, antioxidant, and wound healing in alleviating hemorrhoidal symptoms is discussed in this review. Therapeutically notable plants such as witch hazel (Hamamelis virginiana), horse chestnut (Aesculus hippocastanum), and triphala have shown beneficial therapeutic effects on pain, bleeding, and swelling, as well as preventing recurrence. Moreover, Triphala Guggulu and Pilex are polyherbal formulations that offer synergistic benefits in addition to foods rich in polyphenols and the dietary compound, rutin. These promising findings have so far faced challenges related to the standardization, quality control, and clinical validation. The incorporation of these herbal therapies into clinical practice is a well-tolerated holistic approach to the management of hemorrhoids, which requires further investigation to gain evidence-based validation.
Abstract licence: CC BY
M. Wójciak, Wiktoria Pacuła, I. Sowa, et al.
Molecules, 2025
Hamamelis virginiana L. (witch hazel) is a traditionally used medicinal plant, well-known for its dermatological applications. The plant’s bark and leaves contain a rich array of bioactive compounds, including phenolic acids, flavonoids, catechins, proanthocyanidins, and tannins, many of which exhibit antimicrobial, anti-inflammatory, antioxidant, and wound-healing properties. These activities have been verified by numerous in vitro and in vivo studies, as well as limited clinical trials. The H. virginiana extracts have demonstrated effectiveness against bacteria, fungi, and some viruses. Moreover, the extracts exert anti-inflammatory effects by modulating cytokine expression and NF-κB signaling, improve skin regeneration, and protect against UV-induced damage and pollution. This review highlights H. virginiana as a complex botanical resource to be used in dermatology and cosmetology and shows that current research offers encouraging results for its future therapeutic use, especially in skin treatment.
Abstract licence: CC BY
Letícia Apolinário Carlos da Silva, Mirella Camargo do Nascimento, Thais Ranielle Souza de Oliveira
Scientific Electronic Archives, 2024
This study examines the risks and harms associated with the use of naphazoline hydrochloride (NHC). The methodology involved a narrative literature review from 2013 to 2023 in Portuguese, English, and Spanish, which identified eleven relevant articles from Scielo, Medline Complete, PubMed, and Google Scholar. The guiding question was: What are the risks and potential adverse effects associated with the use of NHC? Results and Discussion: Pharmacists play a crucial role in educating against misuse and promoting responsible medication use. However, challenges arise due to the prevalence of self-medication and limited pharmacist involvement in prescribing. The Role of Pharmacists: Harms of Misuse: Key concerns identified include systemic effects, drug-induced rhinitis, and dependence. Overuse of NHC during pregnancy and in children can lead to serious consequences such as hypothermia, bradycardia, and nervous system depression. The abuse hazards of NHC include rebound effects, drug-induced rhinitis, and long-term health risks such as hypertension and heart problems. Conclusion: The study emphasizes the pressing need for enhanced pharmacist training to equip them to effectively counsel and prevent misuse. Additionally, increased public awareness campaigns should be implemented to promote responsible non-prescription healthcare (NHC) use. Stricter dispensing measures, such as regulations to restrict over-the-counter access, should also be put in place. It is essential to promote responsible NHC use. Pharmacists play a critical role in mitigating the risks associated with this widely used medication as public health educators and patient guides.
Abstract licence: CC BY 4.0
Qianqian Kong, Huanhuan Zhang, Zhenluo Yuan, et al.
ACS Sustainable Chemistry & Engineering, 2020
B. Kuzminov, Vira Turkina, Y. Кuzminov
Current Issues in Pharmacy and Medical Sciences, 2018
Robert Skopec
Journal of Bio Innovation, 2020
L. Theisen, C. Erdelmeier, Gilles A. Spoden, et al.
PLoS ONE, 2014
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.